Inmagene: IMG-007 Shows Promise in Alopecia Areata Phase 2a Study
Inmagene Biopharmaceuticals announced positive topline results from a Phase 2a trial of IMG-007, a non-depleting anti-OX40 monoclonal antibody, in...
NorthStrive IND for EL-22 & GLP-1RA Phase 2 Obesity Trial Gets FDA Nod
Northstrive Biosciences, a subsidiary of PMGC Holdings, received positive feedback from the FDA regarding its pre-IND meeting request for...
Spyglass Pharma’s IOL Delivers Compelling 18-Month Visual Acuity Results
SpyGlass Pharma announced positive 18-month data from its first-in-human study of a novel drug delivery platform for glaucoma and...
Bioxodes Announces Positive Phase 2a Interim Data for BIOX-101
Bioxodes SA announced positive interim results from its Phase 2a BIRCH trial of BIOX-101 for intracerebral hemorrhagic stroke (ICH)....
Mineralys Therapeutics Publishes Pivotal Phase 2 ADVANCE-HTN Results in NEJM
Mineralys Therapeutics announced positive Phase 2 Advance-HTN trial results for lorundrostat, a novel treatment for uncontrolled or resistant hypertension...
Oncology Institute & Helios Partner to Expand Cancer Trials
The Oncology Institute (TOI) is expanding its partnership with Helios Clinical Research to bring clinical trials to more community...
Dexter Surgical Robot: Distalmotion Advances with Milestones
Distalmotion, a MedTech company specializing in robotic surgery, has completed clinical trials for cholecystectomy and benign hysterectomy in the...
AP Biosciences Doses First Patient in AP402 Phase 1/2 Trials
AP Biosciences has dosed the first patient in a Phase 1 trial of AP402, a novel T cell engager...
March Biosciences MB-105 Dosed in First T-Cell Lymphoma Patient
March Biosciences has dosed the first patient in a Phase 2 clinical trial for MB-105, a CD5-targeted CAR-T cell...
Kymera Doses First Patient in KT-621 Atopic Dermatitis Trial
Kymera Therapeutics has initiated its BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader, in patients with...